ImmunityBio (IBRX) EBITDA (2014 - 2026)
ImmunityBio (IBRX) reported EBITDA of -$69.8 million for Q1 2026, down 8.32% year-over-year from -$76.1 million in Q1 2025, and down 7.9% on a QoQ basis from -$64.7 million in Q4 2025.
ImmunityBio (IBRX) has 13 years of EBITDA data on file, last reported at -$69.8 million in Q1 2026.
- Quarterly EBITDA fell 8.32% year-over-year to -$69.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$261.4 million (up 16.6% YoY) and the FY2025 annual result came in at -$256.0 million, up 25.61% from the prior year.
- EBITDA eased to -$69.8 million in Q1 2026 per IBRX's latest filing, from -$64.7 million in the prior quarter.
- Across five years, EBITDA topped out at -$55.6 million in Q3 2025 and bottomed at -$111.6 million in Q1 2023.
- The 5-year median for EBITDA is -$80.3 million (2024), against an average of -$81.4 million.
- The widest annual swing landed in 2024, when EBITDA dropped 16.66%; it then jumped 32.32% in 2025.
- Tracing IBRX's EBITDA over 5 years: stood at -$84.9 million in 2022, then fell by 0.58% to -$85.4 million in 2023, then gained by 18.72% to -$69.4 million in 2024, then advanced by 6.8% to -$64.7 million in 2025, then retreated by 7.9% to -$69.8 million in 2026.
- Per Business Quant, the three latest IBRX EBITDA figures stand at -$69.8 million (Q1 2026), -$64.7 million (Q4 2025), and -$55.6 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -13.63 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -19.70 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -14.44 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 1.14 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | -3.82 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 661.60 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 201.19 Mn |
| 10 | ImmunityBio | 7.72 Bn | 7.34 Bn | 43.97 Mn | -69.79 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -69.79 Mn |
| Dec 31, 2025 | -64.68 Mn |
| Sep 30, 2025 | -55.63 Mn |
| Jun 30, 2025 | -71.29 Mn |
| Mar 31, 2025 | -64.43 Mn |
| Dec 31, 2024 | -69.40 Mn |
| Sep 30, 2024 | -80.25 Mn |
| Jun 30, 2024 | -99.33 Mn |
| Mar 31, 2024 | -95.20 Mn |
| Dec 31, 2023 | -85.39 Mn |
| Sep 30, 2023 | -80.14 Mn |
| Jun 30, 2023 | -85.15 Mn |
| Mar 31, 2023 | -111.58 Mn |
| Dec 31, 2022 | -84.90 Mn |
| Sep 30, 2022 | -90.80 Mn |
| Jun 30, 2022 | -79.62 Mn |
| Mar 31, 2022 | -95.97 Mn |
| Dec 31, 2021 | -79.27 Mn |
| Sep 30, 2021 | -78.84 Mn |
| Jun 30, 2021 | -85.91 Mn |
| Mar 31, 2021 | -86.26 Mn |
| Dec 31, 2020 | -30.89 Mn |
| Sep 30, 2020 | -65.88 Mn |
| Jun 30, 2020 | -50.92 Mn |
| Mar 31, 2020 | -36.70 Mn |
| Dec 31, 2019 | -16.11 Mn |
| Sep 30, 2019 | -16.07 Mn |
| Jun 30, 2019 | -17.30 Mn |
| Mar 31, 2019 | -18.34 Mn |
| Dec 31, 2018 | -17.72 Mn |
| Sep 30, 2018 | -24.11 Mn |
| Jun 30, 2018 | -28.28 Mn |
| Mar 31, 2018 | -28.28 Mn |
| Dec 31, 2017 | -25.39 Mn |
| Sep 30, 2017 | -24.44 Mn |
| Jun 30, 2017 | -23.82 Mn |
| Mar 31, 2017 | -25.46 Mn |
| Dec 31, 2016 | -25.14 Mn |
| Sep 30, 2016 | -32.78 Mn |
| Jun 30, 2016 | -34.97 Mn |
| Mar 31, 2016 | -31.62 Mn |
| Dec 31, 2015 | -29.92 Mn |
| Sep 30, 2015 | -46.46 Mn |
| Jun 30, 2015 | -130.40 Mn |
| Mar 31, 2015 | -32.10 Mn |
| Dec 31, 2014 | -2.63 Mn |
| Sep 30, 2014 | -919,000.00 |
| Jun 30, 2014 | -1.20 Mn |
| Mar 31, 2014 | -826,000.00 |